The safety and feasibility of preoperative induction therapy of Savolitinib in non-small cell lung cancer patients with MET exon 14 skipping mutation
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00432-022-04370-x.pdf
Reference20 articles.
1. Choueiri TK, Heng DYC, Lee JL, Cancel M, Verheijen RB, Mellemgaard A et al (2020) Efficacy of Savolitinib vs Sunitinib in patients with MET-driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial. JAMA Oncol 6(8):1247–1255
2. Deng HY, Li D, Ren Y, Wang K, Tang X (2021) Targeted therapy followed by salvage surgery and adjuvant therapy: a promising therapy for lung cancer with malignant pleural effusion from a case report. Front Surg 8:659983
3. Dhillon S (2020) Capmatinib: first approval. Drugs 80(11):1125–1131
4. Group NM-aC (2014) Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 383(9928):1561–1571
5. Guo R, Luo J, Chang J, Rekhtman N, Arcila M, Drilon A (2020) MET-dependent solid tumours—molecular diagnosis and targeted therapy. Nat Rev Clin Oncol 17(9):569–587
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Neoadjuvant savolitinib targeted therapy for stage IIIB-N3 lung adenocarcinoma harboring mesenchymal–epithelial transition exon 14 skipping mutation: a case report and literature review;Anti-Cancer Drugs;2024-02-23
2. Savolitinib: A Promising Targeting Agent for Cancer;Cancers;2023-09-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3